Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furosemide and sevelamer interaction study in hemodialysis patients
NL-OMON33060Active, not recruiting
- Sponsor
- Canisius-Wilhelmina Hospital
- Start
- Jun 2011
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label trial of furosemide and sevelamer carbonate in end-stage kidney disease (ESKD) (2 arms), sponsored by Canisius-Wilhelmina Hospital. Primary endpoints: 24-hour urine volume and Urinary furosemide concentration. Started Jun 2011; status: active, not recruiting.
02
Drugs
furosemidesevelamer carbonate
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NL-OMON33060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33060.